The FDA accepted a resubmission for T cell immunotherapy tab-cel while simultaneously rejecting approval for Rocket's gene therapy Kresladi.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA accepted a resubmission for T cell immunotherapy tab-cel while simultaneously rejecting approval for Rocket's gene therapy Kresladi.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Food and Drug Administration
government organization in Nonthaburi, Thailand
-
Atara Biotherapeutics, Inc.
clinical-stage biotechnology company
Nothing else this week.
-
Rocket
Nothing else this week.
Coverage
Newest first; wire copies grouped- BioPharma DiveRocket lays off staff; Abivax capitalizes on immune drug data This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive new